# Clinical Trial Imaging - Global Strategic Business Report 2026: Capitalize on the $1.3 Billion Market as Bioclinica, Icon PLC, Parexel, and Ixico Disrupt AI-Driven Trials by 2032

- Published: 2026-11-16
- Author: [Healthcare News](https://healthcarenews.io/author/healthcarenews-io.md)
- Topics: [News](https://healthcarenews.io/news.md)
- Source: https://healthcarenews.io/news/clinical-trial-imaging-global-strategic-business-report-2026-capitalize-on-the-1-3-billion/
- Publication: Healthcare News
- Publisher: Connectively (Terkel, Inc.)
- Editorial policy: https://healthcarenews.io/editorial-policy/

*Boost trial ROI with AI-powered image analysis, cloud collaboration and decentralized workflows, while targeting high-demand oncology and neurology applications.*

Dublin, Nov. 16, 2026 [(GLOBE NEWSWIRE)](https://www.globenewswire.com) -- <a href="https://www.researchandmarkets.com/reports/5303292/clinical-trial-imaging-global-strategic?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=r78dv8&amp;utm_campaign=2404488+-+Clinical+Trial+Imaging+-+Global+Strategic+Business+Report+2026%3a+Capitalize+on+the+%241.3+Billion+Market+as+Bioclinica%2c+Icon+PLC%2c+Parexel%2c+and+Ixico+Disrupt+AI-Driven+Trials+by+2032&amp;utm_exec=clshmsai" rel="nofollow">"Clinical Trial Imaging - Global Strategic Business Report 2026"</a> has been added to **ResearchAndMarkets.com's** offering.

**Global Clinical Trial Imaging Market to Reach US$1.3 Billion by 2032**

The global clinical trial imaging market was valued at US$931.2 million in 2025 and is projected to reach US$1.3 billion by 2032, expanding at a compound annual growth rate (CAGR) of 5.1%. Growth is being supported by increasingly complex clinical trial protocols, technological advances in medical imaging, rising chronic disease prevalence, and broader regulatory acceptance of imaging-based clinical endpoints.

**Clinical Trial Imaging Market Trends and Growth Drivers**

Clinical trial imaging plays a critical role in generating accurate, quantifiable evidence for evaluating treatment efficacy and safety. MRI, CT, PET, ultrasound, functional imaging, and other modalities enable researchers to monitor anatomical, physiological, and molecular changes throughout a study. Imaging is particularly important in therapeutic areas where objective measurement of disease progression and treatment response can strengthen trial reliability and regulatory submissions.

Artificial intelligence and machine learning are transforming image analysis through automation, quantitative assessment, and advanced pattern recognition. These technologies can improve consistency, identify subtle changes over time, and support faster clinical decision-making. Cloud computing, digital storage, and remote collaboration platforms are also facilitating centralized image review across global trial sites. Meanwhile, 3D imaging and digital biomarkers are creating additional opportunities for detailed disease measurement and more precise study endpoints.

Oncology remains a major source of demand as sponsors use imaging to monitor tumor progression, metastasis, and response to emerging therapies. Neurology studies rely on imaging to evaluate structural and functional changes associated with Alzheimer's disease, Parkinson's disease, multiple sclerosis, and other neurological conditions. Imaging also supports cardiology trials assessing cardiac function and blood flow, as well as musculoskeletal studies tracking changes related to osteoarthritis, rheumatoid arthritis, and other disorders.

Market expansion is further supported by the growth of decentralized clinical trials and digitally connected research models. Remote image acquisition, centralized reading, and integration with digital trial workflows can broaden patient access while improving operational efficiency. The increasing prevalence of cancer, cardiovascular disease, neurological disorders, and degenerative conditions is expected to sustain demand for clinical trial imaging services through 2032.

**Market Segment and Regional Outlook**

-   **Project and Data Management:** This service segment is forecast to reach US$435 million by 2032, growing at a CAGR of 5.8%.
-   **Operational Imaging Services:** The segment is projected to expand at a CAGR of 4.6% during the analysis period.
-   **United States:** The U.S. clinical trial imaging market was valued at US$253.7 million in 2025.
-   **China:** China is forecast to grow at a CAGR of 8.8%, reaching US$282.9 million by 2032.
-   **Additional Markets:** The report provides analysis of Canada, Japan, Germany, wider Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

**Report Scope**

The report analyzes the clinical trial imaging market by value in US dollars and includes annual sales data and forecasts from 2025 through 2032.

-   **Services:** Project and data management, operational imaging services, reading and analytical services, clinical trial design and consultation, and system and technology support.
-   **End Users:** Contract research organizations, biotechnology and pharmaceutical companies, medical device manufacturers, academic and government research institutes, and other end users.
-   **Geographic Coverage:** United States, Canada, Japan, China, Europe, Asia-Pacific, Latin America, the Middle East, and Africa, with country-level analysis across major markets.

**Strategic Value of the Clinical Trial Imaging Market Report**

-   Independent market analysis covering major services, end users, countries, and regions.
-   Assessment of competitive conditions and the geographic presence of leading clinical trial imaging companies.
-   Analysis of emerging technologies, market drivers, constraints, and revenue opportunities.
-   Forecasts designed to support investment planning, market entry, partnership development, and competitive strategy.
-   One year of complimentary updates covering relevant market developments.

**Key Questions Addressed**

-   How will the global clinical trial imaging market develop through 2032?
-   Which technologies and therapeutic areas will have the greatest influence on market growth?
-   Which service and end-use segments are expected to expand most rapidly?
-   How will regional market dynamics and competitive positions change?
-   Which companies are shaping the clinical trial imaging competitive landscape?

**Companies Featured**

Featured companies include Bioclinica, Inc.; Biomedical Systems Corporation; Biotelemetry, Inc.; Cardiovascular Imaging Technologies, LLC; ERT Clinical; Icon PLC; Image Core Lab; Intrinsic Imaging LLC; Ixico PLC; Lyscaut Medical Imaging Company; Medical Metrics; Navitas Life Sciences; Parexel International Corporation; Perspectum Diagnostics; Prism Clinical Imaging; Quotient Sciences; Radiant Sage LLC; Resonance Health; and Worldcare Clinical, LLC.

**Domain Expert Insights**

-   The analysis incorporates perspectives from domain experts across industry, enterprise, and academia.
-   The report tracks early market signals emerging from expert discussions, company activity, corporate disclosures, conferences, keynotes, panel sessions, annual reports, institutional publications, and other validated sources.
-   Expert perspectives are connected with strategic market developments to identify growth catalysts, competitive shifts, and issues likely to influence future investment decisions.
-   Company-level intelligence provides insight into businesses participating in and shaping the clinical trial imaging market.
-   Market share analysis is applied where relevant, including regional assessments that reflect differences in competitive structure and market dynamics.

**Key Attributes:**  
  

| Report Attribute | Details |
| --- | --- |
| No. of Pages | 261 |
| Forecast Period | 2025 - 2032 |
| Estimated Market Value (USD) in 2025 | $931.2 Million |
| Forecasted Market Value (USD) by 2032 | $1300 Million |
| Compound Annual Growth Rate | 5.1% |
| Regions Covered | Global |

  
For more information about this report visit <a href="https://www.researchandmarkets.com/reports/5303292/clinical-trial-imaging-global-strategic?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=r78dv8&amp;utm_campaign=2404488+-+Clinical+Trial+Imaging+-+Global+Strategic+Business+Report+2026%3a+Capitalize+on+the+%241.3+Billion+Market+as+Bioclinica%2c+Icon+PLC%2c+Parexel%2c+and+Ixico+Disrupt+AI-Driven+Trials+by+2032&amp;utm_exec=clshmsai" rel="nofollow">https://www.researchandmarkets.com/r/w6fuan</a>

**About ResearchAndMarkets.com**  
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: 
CONTACT: ResearchAndMarkets.com 
         Laura Wood,Senior Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900 

  
![](https://ml.globenewswire.com/media/YmM1YTE5ZmYtMWQ3MC00MDJmLWFlNzEtZTU5ZjVlZjk5Y2ZmLTEwMjY3MzctMjAyNi0xMS0xNi1lbg==/tiny/Research-and-Markets.png)

## Related

- [E-Clinical Trial Technologies - Global Strategic Business Report 2026: Capitalize on 16.6% CAGR to US$32.8 Billion by 2032 as Oracle, Medidata, BioClinica and PAREXEL Disrupt Digital Trials](https://healthcarenews.io/news/e-clinical-trial-technologies-global-strategic-business-report-2026-capitalize-on-16-6-cag.md)
- [Genomic Clinical Decision Support Market Size, Share, Trends, and Forecast, 2026-2036 | AI, EHR Integration, and Pharmacogenomics Drive 13.8% CAGR to USD 5.18 Billion by 2036](https://healthcarenews.io/news/genomic-clinical-decision-support-market-size-share-trends-and-forecast-2026-2036-ai-ehr-i.md)
- [Global Point of Care (POC) Immunoassay Analyzer Expansion Market 2026 | Capture 8.8% CAGR to 2030 as Roche, Abbott, Siemens Healthineers and Danaher Scale AI-Enabled POC Testing](https://healthcarenews.io/news/global-point-of-care-poc-immunoassay-analyzer-expansion-market-2026-capture-8-8-cagr-to-20.md)
- [In Vivo Imaging Systems Market - Global Forecast 2026-2032 | AI and Multimodal Platforms Drive 12.68% CAGR, Creating a USD 3.86 Billion Opportunity by 2032](https://healthcarenews.io/news/in-vivo-imaging-systems-market-global-forecast-2026-2032-ai-and-multimodal-platforms-drive.md)
